Claims for Patent: 5,580,776
✉ Email this page to a colleague
Summary for Patent: 5,580,776
| Title: | Modified hepatocytes and uses therefor |
| Abstract: | Genetically engineered or transduced hepatocytes which express genetic material of interest introduced or incorporated into them, as well as methods of producing, transplanting and using the genetically engineered hepatocytes. The genetic material of interest can be incorporated through use of a vector, such as a recombinant retrovirus, which contains the genetic material of interest, or by other means. |
| Inventor(s): | Wilson; James M. (Ann Arbor, MI), Mulligan; Richard C. (Cambridge, MA) |
| Assignee: | Howard Hughes Medical Institute (Chevy Chase, MD) Whitehead Institute for Biomedical Research (Cambridge, MA) |
| Application Number: | 08/201,721 |
| Patent Claims: | 1. Transduced mammalian hepatocytes having genetic material of interest stably incorporated therein, the transduced hepatocytes having the property of being capable of in vivo
expression of the polypeptide or protein encoded by the genetic material of interest wherein said genetic material comprises a retroviral vector lacking a selectable marker.
2. Transduced mammalian hepatocytes of claim 1 in which the genetic material of interest is selected from the group consisting of: DNA which is present in and expressed by normal hepatocytes; DNA which does not normally occur in hepatocytes; DNA which normally occurs in hepatocytes but is not expressed in them at levels which are biologically significant; and Any DNA which can be modified so that it can be expressed in hepatocytes. 3. Transduced mammalian hepatocytes of claim 1, wherein the genetic material of interest encodes a biologically active protein or polypeptide. 4. Transduced mammalian hepatocytes of claim 3 wherein the genetic material of interest encodes human parathyroid hormone, tissue plasminogen activator, factor VIII, low density lipoprotein receptor or beta-galactosidase. 5. Transduced mammalian hepatocytes according to claim 1 wherein said retroviral vector lacks a selectable marker. 6. A method of making transduced mammalian hepatocytes which express stably incorporated genetic material encoding at least one protein of interest or at least one polypeptide of interest, comprising the steps of: a) contacting the hepatocytes in vitro with media containing an infectious recombinant retrovirus having a recombinant genome comprising the genetic material of interest wherein said genetic material comprises a retroviral vector; and b) maintaining the hepatocytes and the media containing the infectious recombinant retrovirus under non-selective conditions appropriate for infection of the hepatocytes by the recombinant retrovirus, thereby producing transduced hepatocytes. |
Details for Patent 5,580,776
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Takeda Pharmaceuticals U.s.a., Inc. | NATPARA | parathyroid hormone | For Injection | 125511 | January 23, 2015 | ⤷ Get Started Free | 2014-02-25 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
